Literature DB >> 7678028

Lymphokine-activated killer cells. VII. IL-4 induces an NK1.1+CD8 alpha+beta- TCR-alpha beta B220+ lymphokine-activated killer subset.

Z K Ballas1, W Rasmussen.   

Abstract

Murine IL-2-induced lymphokine-activated killers (LAK) can be divided into two mutually exclusive subsets: NK1.1+CD8- and NK1.1-CD8+. We have previously established that the lytically active subset of each of these two populations expressed B220, as determined by the mAb 6B2, on its surface. In this study, we examined the lytically active subsets induced by IL-4. We found that, similar to IL-2, the lytically active IL-4-LAK expressed B220 on their surface. Similar to IL-2-LAK, IL-4-LAK cultures also contained NK1.1+CD8- B220+, and NK1.1-CD8+B220+ subsets. IL-4-LAK cultures, however, contained two novel and unexpected lymphocyte subsets determined by their surface markers to be either: i) NK1.1+CD8 alpha+beta-B220+, or ii) NK1.1-CD8 alpha+beta-B220+. These subsets were not derived from NK1.1+ or CD8+ precursors but were induced from a CD4-CD8-NK1.1-Slg- splenocyte subpopulation. Most of the CD8 alpha+beta- cells seen in the IL-4 cultures expressed TCR-alpha beta with little or no TCR-gamma delta detected on their surface. Similar to IL-2-LAK, the IL-4-LAK subsets appeared to display a bias as to their susceptible target cells with the NK1.1-CD8 alpha+beta+ subset being most potent against trinitrophenyl-modified autologous lymphoblasts (2,4,6-trinitrobenzene sulfonic acid (TNBS)-self). The NK1.1+CD8 alpha-beta- effectors were most potent against YAC-1 and CL27A with little activity against TNBS-self. All three targets were susceptible to lysis by the NK1.1+CD8 alpha+beta- subset. These findings document the characteristics of a novel lymphocyte subset, derived from splenic precursors, which shares certain features with cells previously thought to be present exclusively in intraepithelial lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678028

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  The emergence of non-cytolytic NK1.1+ T cells in the long-term culture of murine tumour-infiltrating lymphocytes: a possible role of transforming growth factor-beta.

Authors:  K Tamada; M Harada; O Ito; M Takenoyama; T Mori; G Matsuzaki; K Nomoto
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

2.  Immune regulation of transgene expression in the brain: B cells regulate an early phase of elimination of transgene expression from adenoviral vectors.

Authors:  Jeffrey M Zirger; Chunyan Liu; Carlos Barcia; Maria G Castro; Pedro R Lowenstein
Journal:  Viral Immunol       Date:  2006       Impact factor: 2.257

3.  Role of macrophage scavenger receptors in hepatic granuloma formation in mice.

Authors:  S I Hagiwara; M Takeya; H Suzuki; T Kodama; L J van der Laan; G Kraal; N Kitamura; K Takahashi
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

4.  IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice.

Authors:  J Marks-Konczalik; S Dubois; J M Losi; H Sabzevari; N Yamada; L Feigenbaum; T A Waldmann; Y Tagaya
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

5.  Utility of antiPax5 in the diagnosis of lymphoproliferative disorders and neoplasia in mice.

Authors:  Jerold E Rehg; John P Sundberg
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

6.  Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice.

Authors:  R J D'Andrea; D Harrison-Findik; C M Butcher; J Finnie; P Blumbergs; P Bartley; M McCormack; K Jones; R Rowland; T J Gonda; M A Vadas
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

Review 7.  Modulation of NK cell activity by CpG oligodeoxynucleotides.

Authors:  Zuhair K Ballas
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

8.  A role for IL-4 in immunologically mediated enteropathy.

Authors:  A M Mowat; M B Widmer
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

9.  Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood.

Authors:  Seok-Gu Kang; Chung Hun Ryu; Sin Soo Jeun; Chun Kun Park; Hyung-Jin Shin; Jong Hyun Kim; Moon Chan Kim; Joon Ki Kang
Journal:  Childs Nerv Syst       Date:  2004-02-13       Impact factor: 1.475

10.  Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand.

Authors:  Brian J Willett; Elizabeth L McMonagle; Nicola Logan; O Brad Spiller; Pascal Schneider; Margaret J Hosie
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.